Overcoming supply challenges in direct-to-patient clinical trials
Evaluate key decisions to mitigate supply chain risks of Direct-to-Patient clinical trials, including shipping coordination and resupply, managing temperature excursions and the importance of technology in study execution
Add bookmark
More and more sponsors are transitioning to Direct-to-Patient (DtP) clinical trials in the wake of Covid-19 to ensure trial continuity and patient safety.
With supply strategies adapting to the pressures of Covid-19, it is critical for sponsors to understand the different approaches and the associated supply risk when conducting DtP trials.
In this whitepaper, 4G Clinical discusses the various DtP models and explores how modern randomization and trial supply management (RTSM) systems can help protect supply chain integrity.
The whitepaper also delves into considerations regarding patient privacy data and global regulations.
Read this whitepaper to:
- Determine if DtP makes sense for your trial(s), and if so, what model suits your needs best
- Assess operational and supply challenges with DtP trials
- Navigate patient privacy concerns and regulatory requirements
- Understand how the RTSM provides full traceability of medication – even at the patient’s home
- Discover how modern RTSMs can provide a consistent, reliable and transparent method to manage the unique requirements of the DtP supply chain
Download your copy now to innovate your clinical trial designs.
